HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Linda A Parker Selected Research

Nausea

2/2022Effect of oleoyl glycine and oleoyl alanine on lithium chloride induced nausea in rats and vomiting in shrews.
1/2022Cannabidiol Interferes with Establishment of Δ9-Tetrahydrocannabinol-Induced Nausea Through a 5-HT1A Mechanism.
11/2021Cannabinoids and Cancer Chemotherapy-Associated Adverse Effects.
1/2021Therapeutic Potential of Cannabidiol, Cannabidiolic Acid, and Cannabidiolic Acid Methyl Ester as Treatments for Nausea and Vomiting.
9/2020Evaluation of repeated or acute treatment with cannabidiol (CBD), cannabidiolic acid (CBDA) or CBDA methyl ester (HU-580) on nausea and/or vomiting in rats and shrews.
7/2020Role of the stress response and the endocannabinoid system in Δ9-tetrahydrocannabinol (THC)-induced nausea.
6/2020Cannabinoid Hyperemesis Syndrome: A Review of Potential Mechanisms.
3/2020Effect of combined doses of Δ9-tetrahydrocannabinol and cannabidiol or tetrahydrocannabinolic acid and cannabidiolic acid on acute nausea in male Sprague-Dawley rats.
2/2020Acute naloxone-precipitated morphine withdrawal elicits nausea-like somatic behaviors in rats in a manner suppressed by N-oleoylglycine.
1/2020Nausea-Induced Conditioned Gaping Reactions in Rats Produced by High-Dose Synthetic Cannabinoid, JWH-018.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Linda A Parker Research Topics

Disease

57Nausea
02/2022 - 04/2002
28Vomiting
02/2022 - 01/2002
4Cannabinoid Hyperemesis Syndrome
01/2022 - 01/2020
4Opioid-Related Disorders (Opiate Addiction)
01/2021 - 07/2012
3Neoplasms (Cancer)
11/2021 - 03/2003
2Shock
07/2017 - 03/2013
1Peripheral Nervous System Diseases (PNS Diseases)
11/2021
1Hyperthermia
01/2021
1Chronic Disease (Chronic Diseases)
09/2020
1Tobacco Use Disorder (Nicotine Dependence)
09/2020
1Anhedonia
09/2020
1Abdominal Pain (Pain, Abdominal)
06/2020
1Familial cyclic vomiting syndrome
06/2020
1Body Weight (Weight, Body)
02/2020
1Diarrhea
02/2020
1Brain Concussion (Cerebral Concussion)
01/2020
1Inflammation (Inflammations)
11/2018
1Hyperalgesia
11/2018
1Pain (Aches)
11/2018
1Edema (Dropsy)
11/2018
1Anxiety Disorders (Anxiety Disorder)
01/2018
1Obesity
01/2017
1Medically Unexplained Symptoms
01/2016

Drug/Important Bio-Agent (IBA)

29CannabinoidsIBA
11/2021 - 04/2002
17Lithium ChlorideIBA
02/2022 - 04/2002
15Dronabinol (THC)FDA LinkGeneric
01/2022 - 01/2004
14AntiemeticsIBA
02/2022 - 07/2004
14CannabidiolIBA
01/2022 - 04/2002
12CB1 Cannabinoid Receptor (CB1 Receptor)IBA
01/2020 - 01/2004
10cannabidiolic acidIBA
01/2021 - 08/2014
10EndocannabinoidsIBA
07/2020 - 02/2008
9Pharmaceutical PreparationsIBA
07/2020 - 10/2006
8Ondansetron (Zofran)FDA LinkGeneric
07/2018 - 07/2004
8LithiumIBA
02/2008 - 03/2003
7Morphine (MS Contin)FDA LinkGeneric
02/2022 - 01/2002
7muskIBA
02/2022 - 01/2002
7EmeticsIBA
01/2014 - 04/2002
6fatty-acid amide hydrolase (fatty acid amide hydrolase)IBA
01/2019 - 08/2011
5Serotonin (5 Hydroxytryptamine)IBA
09/2020 - 03/2003
5Monoacylglycerol LipasesIBA
07/2018 - 04/2012
4Naloxone (Narcan)FDA LinkGeneric
02/2022 - 02/2020
45-HT1A Serotonin ReceptorIBA
01/2022 - 06/2011
4SaccharinIBA
09/2020 - 06/2011
4anandamide (arachidonylethanolamide)IBA
09/2020 - 02/2007
4RimonabantIBA
11/2018 - 07/2004
4Glycerol (Glycerine)FDA LinkGeneric
01/2016 - 04/2012
4cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester (URB597)IBA
10/2015 - 02/2007
3Fatty Acids (Saturated Fatty Acids)IBA
02/2022 - 09/2020
3AmidesIBA
02/2022 - 09/2020
3EstersIBA
01/2021 - 01/2018
3N-oleoylglycineIBA
01/2021 - 01/2020
3AutoreceptorsIBA
07/2018 - 05/2009
3MJN110IBA
07/2018 - 02/2015
3SolutionsIBA
09/2008 - 05/2003
2Glycine (Aminoacetic Acid)FDA LinkGeneric
02/2022 - 09/2020
2Alanine (L-Alanine)FDA Link
02/2022 - 09/2020
2HU-580IBA
09/2020 - 01/2018
2MK-886IBA
03/2020 - 10/2015
2PF 3845IBA
01/2019 - 10/2015
2GW 7647IBA
01/2019 - 11/2017
2glyceryl 2-arachidonate (2-arachidonoylglycerol)IBA
07/2018 - 03/2016
28-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT)IBA
01/2018 - 06/2011
2Aprepitant (Emend)FDA Link
01/2016 - 08/2014
2AM 251 (AM251)IBA
10/2013 - 04/2012
2Cannabinoid Receptor AgonistsIBA
08/2011 - 03/2003
2Amphetamine (Amfetamine)FDA LinkGeneric
04/2007 - 01/2002
1N- (2- (4- (2- methoxyphenyl)- 1- piperazinyl)ethyl)- N- (2- pyridinyl)cyclohexanecarboxamideIBA
01/2022
1nabilone (Cesamet)FDA Link
11/2021
1SugarsIBA
01/2021
1PPAR alphaIBA
03/2020
1AcidsIBA
03/2020
1SC 24IBA
02/2020
11-pentyl-3-(1-naphthoyl)indoleIBA
01/2020
1CorticosteroneIBA
01/2020
1Peroxisome Proliferator-Activated Receptors (PPAR)IBA
01/2019
13- (4- t- butylphenyl)- N- (2,3- dihydrobenzo(b)(1,4)dioxin- 6- yl)acrylamideIBA
11/2018
1Transient Receptor Potential ChannelsIBA
11/2018
1CarrageenanIBA
11/2018
11-(3-chlorophenyl)biguanideIBA
07/2018
15-HT3 Serotonin Receptors (5 HT3 Receptor)IBA
07/2018
1tetralinIBA
01/2018
1Anti-Anxiety Agents (Anxiolytics)IBA
01/2018
1Serotonin 5-HT1 Receptor AntagonistsIBA
01/2018
1URB937IBA
11/2017
1lorcaserinIBA
01/2017
15-HT2C Serotonin ReceptorIBA
01/2017
1Serotonin 5-HT2 Receptor AgonistsIBA
01/2017
1CB2 Cannabinoid ReceptorIBA
09/2016
1HU 308IBA
09/2016
1iodopravadoline (AM 630)IBA
09/2016
1EnzymesIBA
03/2016
1MonoglyceridesIBA
01/2016
1Lipase (Acid Lipase)FDA Link
01/2016
1Neurokinin-1 Receptor AntagonistsIBA
08/2014
1cannabidivarinIBA
10/2013

Therapy/Procedure

17Drug Therapy (Chemotherapy)
11/2021 - 04/2002
1Baths
06/2020
1Injections
01/2020
1Oral Administration
09/2016
1Therapeutics
04/2016